At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
hu14.18-IL2 +1 moredrug
Likely dose
hu14.18-IL2 6 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Trial of HU14.18-IL2 (EMD273063) in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma
In Brief
A Phase 2 clinical trial evaluating hu14.18-IL2 for Melanoma. Completed, enrolled 23 participants across 1 site.
Detailed Summary
Evaluate the antitumor activity of hu14.18-IL2 in the minimal residual disease setting. Evaluate the time to recurrence and overall survival of patients treated with hu14.18-IL2.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), EMD Serono
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedJan 2008
Primary CompletionSep 2018
TodayJul 2026
First PostedJan 11, 2008
Enrollment StartDec 17, 2007
Primary CompletionSep 20, 2018
TodayJul 2, 2026
Enrollment to primary: 10.8 yearsPosted 18.5 years ago
Interventions
hu14.18-IL2drug
6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
hu14.18-IL2drug
Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course